Click Here to Register


Overview

Join a 60-minute roundtable on the impact of antimicrobial resistance (AMR) in cancer care. Experts will discuss recent research, share key takeaways, and explore how stewardship and infection prevention can help protect patients.

Speakers

  • Vikas Gupta, PharmD, FIDSA: Dr. Gupta is senior director of clinical affairs at Q-Linea. He is a clinical pharmacist with experience in patient care and developing and implementing clinical programs in academic and non-academic settings. Lead author of the Cancer Medicine and The Lancet Oncology publications.
  • Yehoda Martei MD, MSCE: Dr. Martei is a medical oncologist, an assistant professor of Medicine, and the Vice for Global Oncology in the Division of Hematology and Oncology at the University of Pennsylvania. She is also a global health scholar at the Center for Global Health and a senior fellow at the Leonard Davis Institute of Health Economics at Penn. She is an adjunct lecturer at the University of Botswana where she conducts most of her research work related to access to essential medicines for cancer treatment. Dr. Martei is a co-author on the related publications.
  • Michael Satlin, MD, MS: Dr. Satlin is Clinical Director of the Transplantation-Oncology Infectious Diseases Program at Weill Cornell and provides infectious diseases supportive care to immunocompromised hosts. Dr. Satlin's research interests are in epidemiology, diagnosis, and treatment of multidrug-resistant Gram-negative bacterial infections in immunocompromised hosts, and his research is supported by grants from NIAID and industry. He is Co-Chair of the Breakpoint Working Group of the Clinical and Laboratory Standards Institute's Subcommittee on Antimicrobial Susceptibility Testing, participates on multiple committees of NIAID's Antibacterial Research Leadership Group, and serves on the Program Committee for ASM Microbe. Dr. Satlin is a co-author on the related publications.
  • Michael Craig, MPP: Mr. Craig is the director of the CDC’s Antimicrobial Resistance Coordination and Strategy Unit, which focuses on addressing national goals to combat antimicrobial resistance. He collaborates closely with leadership within the US Department of Health and Human Services to ensure the alignment of public health activities related to antimicrobial resistance across multiple federal agencies.
  • Moderator: Marnie Peterson, PharmD, PhD: Outreach Coordinator for the Antimicrobial Stewardship Project at CIDRAP will serve as moderator

 

Objectives

  1. Understand the findings of the new publications in The Lancet Oncology and Cancer Medicine on AMR and Cancer
  2. Learn about the implications of the new data and potential considerations for clinical guidelines and patient pathways of care
  3. Understand opportunities to further research to analyze the impact of AMR on cancer patients
  4. Understand how the CDC is educating on infection prevention, stewardship, and other actions to reduce the burden of AMR

 

Background Materials

  • AMR in hospitalized US patients with cancer: Gupta V et al. Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis. Cancer Med. 2024;13(24):e70495.
  • AMR in US outpatients with cancer: Gupta V et al. Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study. The Lancet Oncology. 2025;26(5):620–8.
  • A literature review: Sallah YH et al. Antimicrobial resistance in patients with haematological malignancies: a scoping review. The Lancet
    Oncology. 2025;26(5):e242–e52.
  • The Lancet Oncology editorial that ties the papers together: Shropshire WC and Shelburne SA. Antimicrobial resistance: a problem across the cancer care continuum. The Lancet Oncology. 2025;26(5):537–8.

 

Click here to Register

 

This activity is supported by an unrestricted educational grant from Becton Dickinson.

Our underwriters

Grant support for ASP provided by

Unrestricted financial support provided by

Become an Underwriter